Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: A clinical experience in 108 patients with metastatic breast cancer-Reference-Cited by-同舟云学术

Array CGH and PIK3CA/AKT1 mutations to drive patients to specific targeted agents: A clinical experience in 108 patients with metastatic breast cancer

Published:2012-10 Issue:15 Volume:48 Page:2293-2299
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Arnedos M.,Scott V.,Job B.,De La Cruz J.,Commo F.,Mathieu M.C.,Wolp-Diniz R.,Richon C.,Campone M.,Bachelot T.,Dalenc F.,Dessen P.,Lacroix L.,Lazar V.,Soria J.C.,Delaloge S.,Andre F.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference24 articles.

1. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

2. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial – INTACT 1;Giaccone;J Clin Oncol,2004

3. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer;Miles;J Clin Oncol,2010

4. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer;Robert;J Clin Oncol,2011

5. North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer;Perez;Ann Oncol,2010

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Durable Clinical Activity to the AKT Inhibitor Ipatasertib in a Heavily Pretreated Patient With an AKT1 E17K Mutant Metastatic Breast Cancer;Clinical Breast Cancer;2021-06

2. Image-guided tumour biopsies in a prospective molecular triage study (MOSCATO-01): What are the real risks?;European Journal of Cancer;2018-11

3. Cancer Molecular Screening and Therapeutics (MoST): a framework for multiple, parallel signal‐seeking studies of targeted therapies for rare and neglected cancers;Medical Journal of Australia;2018-08-27

4. Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients;Medicine;2017-05

5. High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial;Cancer Discovery;2017-04-01